Filed with ASX · · 102 pages · English
Invex Therapeutics Ltd. has issued a notice for an upcoming General Meeting of Shareholders, scheduled for early December. The agenda includes several resolutions, such as approvals for significant asset acquisitions and share issuances related to a transaction with Rekover Therapeutics. Shareholders are advised to review the Independent Expert’s Report regarding the fairness of these transactions before voting. The notice also outlines the process for voting by proxy and in person, emphasizing the importance of shareholder participation.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
All Registry communications to: Automic Group GPO Box 5193 Sydney NSW 2001 Telephone (free call within Australia): 1300 288 664 ASX Code: IXC 4 November 2026 Upcoming General Meeting of Shareholders Dear Shareholder, Invex Therapeutics Ltd ACN 632 145 334 (ASX: IXC or “the Company”), advises a...
Invex Therapeutics Ltd. on 6ix
Follow Invex Therapeutics into a list and get an email when it puts out news.
Follow Invex Therapeutics